Prevail Therapeutics
OverviewSuggest Edit
Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease. It establishes a pipeline of programs that includes discovery-phase and preclinical development efforts.
| Type | Public | |
| Founded | 2017 | |
| HQ | New York, US | Map |
| Website | prevailtherapeutics.com |
Recent NewsAll News
- Prevail Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
- Prevail Therapeutics to Present at Upcoming Conferences
- Prevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease
- Prevail Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
Key People/Management at Prevail Therapeutics
Asa Abeliovich
CEO & Founder, Director
Franz Hefti
Chief Development Officer
Yong Dai
Chief Technology Officer
Jeffrey Sevigny
Chief Medical Officer
Brett Kaplan
Chief Financial Officer
Emily Minkow
Chief Business Officer
Prevail Therapeutics Office Locations
Prevail Therapeutics has an office in New York
New York, US (HQ)
430 E 29th St #940
Prevail Therapeutics Financials and Metrics
Prevail Therapeutics Revenue
| USD | |
|---|---|
Net income (Q1, 2020) | (18.6m) |
EBIT (Q1, 2020) | (19.3m) |
Market capitalization (27-May-2020) | 578.0m |
Closing stock price (27-May-2020) | 16.9 |
Cash (31-Mar-2020) | 149.6m |
EV | 439.4m |
Prevail Therapeutics's current market capitalization is $578 m.
Annual
Annual
| USD | Y, 2020 |
|---|---|
EV/EBIT | -22.8 x |
EV/CFO | -24.1 x |
Financial Leverage | 1.1 x |
Prevail Therapeutics Online and Social Media Presence
Prevail Therapeutics's Trends
Prevail Therapeutics News and Updates
March 26, 2020
Prevail Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
Dosing Initiated in PROPEL Phase 1/2 Trial of PR001 for Treatment of Parkinson’s Disease with GBA1 Mutations
February 21, 2020
Prevail Therapeutics to Present at Upcoming Conferences
NEW YORK, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that management will present at…
December 26, 2019
Prevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease
NEW YORK, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Adm…
November 12, 2019
Prevail Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
Opened Enrollment of PROPEL Phase 1/2 Trial of PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations
Prevail Therapeutics Blogs
March 03, 2020
Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson’s Disease with GBA1 mutations
Company Will Present at Cowen Healthcare Conference Today NEW YORK , March 03, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, provided an
March 02, 2020
Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation
Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation
Content Import
Mon, 03/02/2020 - 07:01
Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment …
February 12, 2020
Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA
Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA
Content Import
Wed, 02/12/2020 - 07:01
Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA
February 12, 2020 …
February 06, 2020
Prevail Announces Presentations at the 16th Annual WORLDSymposium™ 2020
Prevail Announces Presentations at the 16th Annual WORLDSymposium™ 2020
Content Import
Thu, 02/06/2020 - 08:31
Prevail Announces Presentations at the 16th Annual WORLDSymposium™ 2020
February 6, 2020 at 8:30 AM EST
This release is a backfill from a News Wire
…
January 09, 2020
Prevail Therapeutics Provides PR001 Program Update
Prevail Therapeutics Provides PR001 Program Update
Content Import
Thu, 01/09/2020 - 16:06
Prevail Therapeutics Provides PR001 Program Update
January 9, 2020 at 4:05 PM EST
This release is a backfill from a News Wire
General
PR001 Admi…
December 16, 2019
Prevail Therapeutics Announces FDA Orphan Drug Designation Granted to PR006 for the Treatment of Patients with Frontotemporal Dementia with a GRN Mutation
NEW YORK , Dec. 16, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, announced today that the U.S.
Prevail Therapeutics Frequently Asked Questions
When was Prevail Therapeutics founded?
Prevail Therapeutics was founded in 2017.
Who are Prevail Therapeutics key executives?
Prevail Therapeutics's key executives are Asa Abeliovich, Franz Hefti and Yong Dai.
How many employees does Prevail Therapeutics have?
Prevail Therapeutics has 48 employees.
Who are Prevail Therapeutics competitors?
Competitors of Prevail Therapeutics include Brii Biosciences, Nordic Nanovector and Acousia Therapeutics.
Where is Prevail Therapeutics headquarters?
Prevail Therapeutics headquarters is located at 430 E 29th St #940, New York.
Where are Prevail Therapeutics offices?
Prevail Therapeutics has an office in New York.
How many offices does Prevail Therapeutics have?
Prevail Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies